TITLE

Botulinum A Toxin/Dimethyl Sulfoxide Bladder Instillations for Women With Refractory Idiopathic Detrusor Overactivity: A Phase 1/2 Study

AUTHOR(S)
PETROU, STEVEN P.; PARKER, ALEXANDER S.; CROOK, JULIA E.; ROGERS, ALEXANDRA; METZ-KUDASHICK, DOROTHEA; THIEL, DAVID D.
PUB. DATE
August 2009
SOURCE
Mayo Clinic Proceedings;Aug2009, Vol. 84 Issue 8, p702
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We completed a phase 1/2 trial to evaluate the safety and potential efficacy of direct intravesical instillation of a botulinum type A toxin/dimethyl sulfoxide (DMSO) solution for treatment of idiopathic detrusor overactivity in women. Twenty-five women with medication-resistant, urodynamic-confirmed idiopathic detrusor overactivity were enrolled. A total of 9 patients were treated in phase 1 of the study. Three patients were given a 66% dosing of solution; 22 patients received the full 300 units of botulinum toxin and 50 mL of DMSO (50% concentration). Adverse effects, 24-hour pad weights, episodes of incontinence, postvoid residuals, and scores on the Blalvas-Groutz anti-incontinence scale, Indevus Urgency Severity Scale, Incontinence Impact Questionnaire-short form, and Urogenital Distress inventory (6 items) questionnaire were recorded at baseline, 1 month, and 3 months after instillation. No serious adverse effects or clinically important increases in postvoid residual occurred. Among the 21 women who completed phase 2 of the study, the median number of incontinent episodes decreased from 4 at baseline to 2 at 1 month (P=.004) and increased to 4 at 3 months (P=.81). Median scores Improved from baseline to 1 month on the Incontinence Impact Questionnaire (from 13 to 7; P=.007) and Urogenital Distress inventory (from 10 to 5; P=.003). Although 11 women (52%) reported severe urgency based on the Indevus Urgency Severity Scale at baseline, only 1 (5%; P<.001) and 3 (14%; P=.004) women reported severe scores at 1 and 3 months, respectively. Direct instillation of botulinum toxin/DMSO solution is safe. its promising clinical effect warrants further evaluation in a randomized, placebo-controlled phase 3 setting.
ACCESSION #
43637594

 

Related Articles

  • Botulinum toxin B shows rapid onset, efficacy in OAB. Gagnon, Louise // Urology Times;12/1/2005, Vol. 33 Issue 15, p16 

    The article discusses a study conducted by British researcher James Malon-Lee and colleagues, who found that botulinum toxin type B appears to be more effective for the treatment of over-active bladder, although the agent has a short duration of action. The 20 participants in the study were...

  • Botulinum Toxin Type A for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double-Blind, Placebo-Controlled Trial. Silberstein, Stephen D.; Stark, Stuart R.; Lucas, Sylvia M.; Christie, Suzanne N.; DeGryse, Ronald E.; Turkel, Catherine C. // Mayo Clinic Proceedings;Sep2005, Vol. 80 Issue 9, p1126 

    OBJECTIVES: To identify a treatment-responsive population for botulinum toxin type A (BoNTA) and to evaluate the safety and efficacy of 3 different doses of BoNTA as prophylactic treatment of chronic daily headache (CDH). PATIENTS AND METHODS: A randomized, double-blind, placebo-controlled study...

  • Instillation 'cocktail' appears safe, effective in OAB. Tennant, Scott // Urology Times;7/1/2009, Vol. 37 Issue 8, p10 

    The article focuses on the result of a phase I and II trial conducted by researchers at Mayo Clinic in Jacksonville, Florida. It reveals that direct instillation of a solution that contains botulinum toxin A (Botox) and dimethyl sulfoxide (DMSO [Rimso-50]) may cure women with voiding dysfunction...

  • Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Ã… resolution. Hanson, Michael A.; Stevens, Raymond C. // Nature Structural Biology;Aug2000, Vol. 7 Issue 8, p687 

    Botulinum neurotoxin serotype B is a zinc protease that disrupts neurotransmitter release by cleaving synaptobrevin-II (Sb2), one of three SNARE proteins involved in neuronal synaptic vesicle fusion. The three-dimensional crystal structure of the apo botulinum neurotoxin serotype B catalytic...

  • Uses of botulinum toxin injection in medicine today. Munchau, A.; Bhatia, K. P. // BMJ: British Medical Journal (International Edition);01/15/2000, Vol. 320 Issue 7228, p161 

    Discusses the uses of botulinum toxin injection in modern medicine. Mode of action; Rationale for treatment with botulinum neurotoxin; Side effects of the toxin; Indications for treatment.

  • The many faces of botox. Cohen, Sharon; Kallen, Ben // Shape;Jul2004, Vol. 23 Issue 11, p93 

    Reports on various uses of botulinum toxin.

  • Editors' Response to Johnson. Hooper, David C.; Hirsch, Martin S. // Journal of Infectious Diseases;Sep2014, Vol. 210 Issue 6, p993 

    A response from the editor related to articles regarding the purported new botulinum neurotoxin serotype H published in a 2014 issue is presented.

  • Intravesical botulinum toxin type A in chronic interstitial cystitis: Results of a pilot study. Ramsay, A. K.; Small, D. R.; Conn, I. G. // Surgeon (Edinburgh University Press);Dec2007, Vol. 5 Issue 6, p331 

    Aim: To assess the efficacy of intravesical botulinum toxin type A (BTX-A) in interstitial cystitis (IC). Methods: Eleven patients with IC were injected with BTX-A. Primary outcome measures were: Bristol Female Lower Urinary Tract Symptom Score, Kings Health Questionnaire and 24-hour...

  • Botulinum Toxin A (Botox® Cosmetic): A Review of its Use in the Treatment of Glabellar Frown Lines. Frampton, James E.; Easthope, Stephanie E. // American Journal of Clinical Dermatology;2003, Vol. 4 Issue 10, p709 

    Botox[sup ®] Cosmetic (Botox[sup ®]) is a formulation of the neuromuscular blocking agent botulinum toxin type A (BTX-A). When injected into hyperactive corrugator superciliaris and/or procerus muscles of the face that predominantly control frowning, Botox[sup ®] produces a transient...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics